Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company…


Nuclear technology saves lives, especially in Belgium!

Nuclear energy has become a part of our every day lives, but not solely for electricity production. Over the last century, nuclear technology has …


A user experience of Idylla™, the mini-lab

Idylla™, Biocartis’ fully automated molecular diagnostics system was launched in September 2014. Since then, over 100 units have been sold. We ask…

POPULAR TAGS

Faster cancer diagnosis: new Idylla products

Written by DS on in the category news with the tags , .


Biocartis launched two new products for cancer diagnosis to use with its molecular diagnostics platform Idylla™; a liquid biopsy test and a tissue biopsy test. 

The first product, a ctBRAF Mutation Assay uses blood plasma instead of tissue biopsies as a sample. Fragments of tumor DNA are shed into the blood from primary tumors or metastatic sites. These circulating DNA fragments can be used for diagnostic purposes. This technique has the advantage that the tumor location does not have to be known and that samples can be obtained repeatedly in an easy way. The turnaround time of the assay takes about 90 minutes with less than one minute of hands-on work.

The second one is a NRAS-BRAF-EGFR S492R Mutation Assay using a tissue biopsy. This allows a complete RAS-BRAF analysis in one day, which opens up the route towards faster treatment selection. This assay complements the already CE-marked Idylla™ KRAS Mutation Test (tissue biopsy test). Together, they provide a complete metastatic colorectal cancer (mCRC) mutation analysis. They can detect 39 KRAS and NRAS mutations (“extended RAS”) at high sensitivity.

“Liquid biopsy testing has the potential to significantly improve the early diagnosis and monitoring of cancer and we are now enabling same-day RAS testing. We deliver high precision diagnostics for high precision medicine in virtually any setting, to patients worldwide,” says Rudi Pauwels, CEO Biocartis.

Read more about: , .

RELATED ARTICLES
Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company…


Nuclear technology saves lives, especially in Belgium!

Nuclear energy has become a part of our every day lives, but not solely for electricity production. Over the last century, nuclear technology has …


A user experience of Idylla™, the mini-lab

Idylla™, Biocartis’ fully automated molecular diagnostics system was launched in September 2014. Since then, over 100 units have been sold. We ask…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Turnstone GSK Janssen KU Leuven XpandInnovation Flanders.bio UGent Biowin V-Bio Ventures Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.